Provided are oral pharmaceutical compositions comprising alisporivir at about 15-20% by weight of the composition and water at about 2-15% by weight of the composition. In one embodiment a composition comprises alisporivir at 15-20% by weight of the composition, water at about 4-15% by weight of the composition, a lipophilic component, a surfactant and a hydrophilic component. The compositions can be in the form of capsules or drinkable solutions.